bifeprunox + valproate

Bifeprunox + valproate is a combination therapy consisting of **bifeprunox**, an atypical antipsychotic with partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors, and **valproate** (valproic acid), a widely used mood stabilizer and anticonvulsant[3][4]. The combination has been studied to assess its safety, tolerability, and pharmacokinetic interaction, particularly in subjects with bipolar I disorder, aiming to improve management of acute manic episodes and potentially other psychiatric conditions[1]. Bifeprunox is considered to have a favorable metabolic profile compared to other antipsychotics, while valproate acts as a broad-spectrum mood stabilizer through mechanisms such as increasing brain GABA levels and modulating neuronal excitability[3][4]. The developer of bifeprunox includes Solvay Pharmaceuticals, H Lundbeck, and Wyeth Research, with clinical studies in collaboration with academic centers[3].